Related Experiment Video
Updated: Sep 24, 2025
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
16.0K
CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma
Anupam Kumar1, Esraa Mohamed1, Schuyler Tong2
1Brain Tumor Center, Department of Neurological Surgery, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California.
Summary
Pleomorphic xanthoastrocytoma (PXA), a MAPK-activated glioma, exhibits an immune-rich microenvironment. The chemokine CXCL14 promotes CD8+ T-cell responses, enhancing survival and suggesting PXA
Area of Science:
- Neuro-oncology
- Immunology
- Cancer research
Background:
- The immunosuppressive tumor microenvironment in diffuse glioma hinders immunotherapy efficacy.
- Understanding glioma-associated immune responses is crucial for identifying novel immunomodulatory targets.
- Studying gliomas with robust immune responses can reveal factors promoting T-cell function.
Purpose of the Study:
- To define the tumor-associated immune response in distinct glioma subtypes.
- To identify factors modulating the glioma immune microenvironment.
- To investigate tumor-intrinsic factors that promote CD8+ T-cell responses in glioma.
Main Methods:
- Multiplex immune-profiling, proteomic profiling, and gene expression analysis.
- Utilizing patient-derived glioma cultures.
- Employing an immunocompetent murine model for malignant glioma.
Main Results:
- MAPK-activated pleomorphic xanthoastrocytoma (PXA) showed increased CD8+ T cells, microglia/macrophages, and MHC class I expression compared to IDH-mutant astrocytoma.
- PXA tumors secreted CXCL14, which enhanced CD8+ T-cell chemotaxis and recruitment, prolonging survival.
- High expression of the immunomodulatory molecule B7-H3 was observed in PXA.
Conclusions:
- PXA presents an immune-rich microenvironment, making it a potential candidate for immunotherapeutic modulation.
- CXCL14 is identified as a key factor in the glioma immune microenvironment, driving antitumor CD8+ T-cell responses.
- This study highlights novel targets for enhancing immunotherapy in glioma.
